ReviewPituitary2026
Impact of sex on mortality in patients with pituitary adenomas.
Review in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePituitary adenomas are increasingly diagnosed, with prolactinomas and non-functioning pituitary adenomas (NFPA) representing the large majority. Though most pituitary adenomas are indolent and very few are aggressive overall, mortality rates are higher than in general population. This varies with the type of pituitary adenoma, with the highest standardized mortality ratios in patients with Cushing’s disease (CD). Notably, sex differences in mortality remain controversial for all pituitary adenomas.
methodsA scoping PubMed literature review with studies published in English from 1970 to 2025.
resultsSeveral studies are contradictory, most likely related to methodological variability. Data shows a general trend of higher mortality in women with acromegaly compared to men, particularly in newer studies. There are inconsistent results regarding sex-related differences in mortality among patients with CD, but excess mortality was observed in male patients with CD. Mortality is not well studied in prolactinomas given their generally benign course and studies on sex differences are lacking. Women with NFPA also seem to have excess mortality. Factors explaining the sex differences are not clear for any pituitary adenoma type.
conclusionThough there seems to be a sex impact on mortality rates in pituitary adenomas, most data are conflicting. Prospective studies are needed in order to identify and address predictive factors for mortality differences between sexes.
Indexed as
Identifiers
41644768What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.